Identifying patients using antidepressants for the treatment of depression: A predictive algorithm for use in pharmaceutical and medical claims data.


Journal

Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369

Informations de publication

Date de publication:
03 2019
Historique:
received: 14 06 2018
revised: 05 11 2018
accepted: 18 12 2018
pubmed: 27 1 2019
medline: 11 4 2020
entrez: 26 1 2019
Statut: ppublish

Résumé

Records of antidepressant dispensings are often used as a surrogate measure of depression. However, as antidepressants are frequently prescribed for indications other than depression, this is likely to result in misclassification. This study aimed to develop a predictive algorithm that identifies patients using antidepressants for the treatment of depression. Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) claims data were linked to follow-up questionnaires (completed in 2012-2013) for participants of the 45 and Up Study-a cohort study of residents of New South Wales, Australia, aged 45 years and older. The sample composed participants who were dispensed an antidepressant in the 30 days prior to questionnaire completion (n = 3162). An algorithm based on patient characteristics, pharmaceutical dispensings, and claims for mental health services was built using group-lasso interaction network (glinternet), with self-reported receipt of treatment for depression as the outcome. The predictive performance of the algorithm was assessed via bootstrap resampling. The algorithm composes 15 main effects and 11 interactions, with type of antidepressant dispensed and claims for mental health services the strongest predictors. The ability of the algorithm to discriminate between antidepressant users with and without depression was 0.73. At a predicted probability cut-off of 0.6, specificity was 93.8% and sensitivity was 23.6%. Using this algorithm with a high probability cut-off yields high specificity and facilitates the exclusion of individuals using antidepressants for indications other than depression, thereby mitigating the risk of confounding by indication when evaluating the outcomes of antidepressant use.

Identifiants

pubmed: 30680859
doi: 10.1002/pds.4739
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

354-361

Informations de copyright

© 2019 John Wiley & Sons, Ltd.

Auteurs

Alys Havard (A)

Centre for Big Data Research in Health (CBDRH), UNSW Sydney, Sydney, NSW, Australia.

Peter Straka (P)

School of Mathematics and Statistics, UNSW Sydney, Sydney, NSW, Australia.

Grant Sara (G)

InforMH, System Information and Analytics Branch, NSW Ministry of Health, North Ryde, NSW, Australia.
Northern Clinical School, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.

Sanja Lujic (S)

Centre for Big Data Research in Health (CBDRH), UNSW Sydney, Sydney, NSW, Australia.

Duong T Tran (DT)

Centre for Big Data Research in Health (CBDRH), UNSW Sydney, Sydney, NSW, Australia.

Louisa R Jorm (LR)

Centre for Big Data Research in Health (CBDRH), UNSW Sydney, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH